pancreatin + oryz-aspergillus enzyme + acarbose + metformin + glimepiride + insulin

This is not a distinct, co-formulated drug product or a named regimen. It is a non-specific conservative-treatment intervention label from a Changhai Hospital clinical study of painless chronic pancreatitis, combining pancreatic-enzyme replacement options with glucose-lowering medicines used as clinically indicated for pancreatic exocrine and endocrine insufficiency. The source intervention wording presents pancreatin enteric-coated capsules or an oryz-aspergillus enzyme plus pancreatin tablet as alternative enzyme products, and lists acarbose, metformin, glimepiride, and insulin as antidiabetic medicines; it does not establish that all six substances are supplied together or administered to every participant. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07074379))

Other names

pancreatin + oryz-aspergillus enzyme + acarbose + metformin + glimepiride + insulin